Literature DB >> 11810125

Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease.

P Jouvet1, M Jugie, D Rabier, J Desgrès, P Hubert, J M Saudubray, N K Man.   

Abstract

OBJECTIVE: The authors assessed the efficiency, tolerance and outcome of neonates and children with maple syrup urine disease (MSUD) in acute decompensation managed by endogenous and extracorporeal removal of accumulated MSUD metabolites.
DESIGN: Single center cohort study.
SETTING: Pediatric and neonatal intensive care unit in a tertiary care hospital. PATIENTS: Between January, 1991, and June, 1999, six neonates and six children in acute decompensation of MSUD were included in the study. Each of them had two of the three following criteria: comatose state, gastrointestinal intolerance, leucine plasma levels over 1700 micromol/l.
INTERVENTIONS: Patients were treated by combined nutrition manipulation and continuous venovenous extracorporeal removal therapies (CECRT) including hemofiltration, hemodialysis or hemodiafiltration. A clinical and biological evaluation was performed before, during and following the treatment.
RESULTS: Eleven out of the 12 patients survived. One child had two acute episodes at 6.5 and 9 years old. Eight patients recovered a normal cerebral performance category score. In all cases, plasma leucine level decreased according to a logarithmic mode within 11-24 h hemodiafiltration combined with nutritional support whereas, with nutrition alone after stopping CECRT, the decrease in leucine plasma levels was slower, following a linear mode. Eight patients were supplemented with valine and isoleucine for mean plasma values of 177+/-92 and 68+/-66, respectively.
CONCLUSION: In severe acute decompensation of MSUD, CECRT combined with nutritional support limit central nervous system damage, by dramatically decreasing branched chain amino and keto acid levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11810125     DOI: 10.1007/s00134-001-1124-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  7 in total

1.  Impact of inborn errors of metabolism on admission and mortality in a pediatric intensive care unit.

Authors:  Philippe Jouvet; Guy Touati; Fabrice Lesage; Laurent Dupic; Marisa Tucci; Jean Marie Saudubray; Philippe Hubert
Journal:  Eur J Pediatr       Date:  2006-08-29       Impact factor: 3.183

Review 2.  Nutritional management of patients with urea cycle disorders.

Authors:  R H Singh
Journal:  J Inherit Metab Dis       Date:  2007-11-25       Impact factor: 4.982

Review 3.  Controversies in paediatric continuous renal replacement therapy.

Authors:  Graeme Maclaren; Warwick Butt
Journal:  Intensive Care Med       Date:  2009-01-31       Impact factor: 17.440

4.  Continuous renal replacement therapy in neonates weighing less than 3 kg.

Authors:  Young Bae Sohn; Kyung Hoon Paik; Hee Yeon Cho; Su Jin Kim; Sung Won Park; Eun Sun Kim; Yun Sil Chang; Won-Soon Park; Yoon-Ho Choi; Dong-Kyu Jin
Journal:  Korean J Pediatr       Date:  2012-08-23

5.  Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model.

Authors:  Véronique Phan; Marie-José Clermont; Aicha Merouani; Catherine Litalien; Marisa Tucci; Marie Lambert; Grant Mitchell; Philippe Jouvet
Journal:  Pediatr Nephrol       Date:  2006-03-04       Impact factor: 3.714

6.  Real-world management of maple syrup urine disease (MSUD) metabolic decompensations with branched chain amino acid-free formulas in France and Germany: A retrospective observational study.

Authors:  Pascale de Lonlay; Roland Posset; Ulrike Mütze; Karine Mention; Delphine Lamireau; Manuel Schiff; Aude Servais; Jean Baptiste Arnoux; Anaïs Brassier; Myriam Dao; Claire Douillard; Chris Ottolenghi; Clément Pontoizeau; Federica Miotto; Jeannie Le Mouhaër
Journal:  JIMD Rep       Date:  2021-03-06

7.  Intravenous branched-chain amino-acid-free solution for the treatment of metabolic decompensation episodes in Spanish pediatric patients with maple syrup urine disease.

Authors:  Paula Sánchez-Pintos; Silvia Meavilla; María Goretti López-Ramos; Ángeles García-Cazorla; Maria L Couce
Journal:  Front Pediatr       Date:  2022-08-15       Impact factor: 3.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.